Most Read Articles
01 Apr 2016
Amiodarone is safe and effective for early junctional ectopic tachycardia prophylaxis in paediatric patients following open heart surgery, based on a study.
Jairia Dela Cruz, 05 Mar 2018
Abaloparatide appears to produce significant increases in the bone mass density (BMD), as well as nominal reductions in fractures, in very elderly women with osteoporosis, with a safety profile similar to that in the overall study population, according to a posthoc analysis of the phase III ACTIVE trial.
Jairia Dela Cruz, 09 Jan 2017
The sulfonylurea glimepiride may pose an increased risk of hypoglycaemia in a subgroup of elderly type 2 diabetes (T2D) patients with lower β-cell function when added to a metformin regimen, according to a post-hoc analysis of data from the GENERATION* trial.
Roshini Claire Anthony, 26 Apr 2018

Patients with type 2 diabetes (T2D) experienced reductions in plasma uric acid concentrations and subsequently, fewer gout events following treatment with fenofibrate, according to a post hoc analysis of the FIELD* trial.

Ultra-low-dose intravitreal bevacizumab improves severe, posterior ROP

06 Feb 2018

Using 0.16-mg intravitreal bevacizumab (IVB) has improved severe and posterior retinopathy of prematurity (ROP), with no adverse ocular outcomes occurring in the series, reports a recent study.

IVB injection was performed in 29 eyes of 15 infants. ‘Treatment success’ was defined as complete regression of retinopathy and vascularization into (or laser ablation of) zone 3.

Of the 29 eyes, 23 (79.3 percent) achieved primary success in response to IVB 0.16 mg alone, and 27 (93.1 percent) achieved secondary success, where additional treatment was required. During follow-up, one infant death was recorded due to respiratory disease.

Six of the total number of eyes (20.6 percent) underwent retreatment. Retreatments occurred at a mean of 9.8 weeks following initial IVB (range, 6‒15) and at a mean of 44 weeks postmenstrual age (range, 40‒50).

The authors conducted a retrospective observational case series of consecutive infants who underwent ultra-low-dose IVB injection for the management of ROP at a regional neonatal intensive care unit in the North East of England between November 2013 and August 2016.

IVB has emerged as an effective treatment modality for the management of severe and posterior ROP, but despite evidence of systemic vascular endothelial growth factor suppression and concerns about how this might affect the developing neonate, the optimal dose has remained unknown, according to the authors.

A 2013 study in Taiwan had shown the efficacy and safety of IVB injection in treating prethreshold ROP. Researchers, however, said that laser therapy might still be needed as backup treatment for patients who do not respond to an IVB injection or for those in whom ROP worsen after an IVB injection. [Am J Ophthalmol 2013;155:150-158.e1]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
01 Apr 2016
Amiodarone is safe and effective for early junctional ectopic tachycardia prophylaxis in paediatric patients following open heart surgery, based on a study.
Jairia Dela Cruz, 05 Mar 2018
Abaloparatide appears to produce significant increases in the bone mass density (BMD), as well as nominal reductions in fractures, in very elderly women with osteoporosis, with a safety profile similar to that in the overall study population, according to a posthoc analysis of the phase III ACTIVE trial.
Jairia Dela Cruz, 09 Jan 2017
The sulfonylurea glimepiride may pose an increased risk of hypoglycaemia in a subgroup of elderly type 2 diabetes (T2D) patients with lower β-cell function when added to a metformin regimen, according to a post-hoc analysis of data from the GENERATION* trial.
Roshini Claire Anthony, 26 Apr 2018

Patients with type 2 diabetes (T2D) experienced reductions in plasma uric acid concentrations and subsequently, fewer gout events following treatment with fenofibrate, according to a post hoc analysis of the FIELD* trial.